Immunity against SARS-CoV-2 in immune-suppressed patients: increased risk of insufficient immunological memory or sufficient protection against re-infection?

Key facts

Disease
COVID-19
Start & end year
2020
2023
Funder
Netherlands Organisation for Health Research and Development (ZonMW)
Principal Investigator
dr TW. Prof Kuijpers
Research Location
N/A
Lead Research Institution
Amsterdam UMC - locatie AMC
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Other
Occupations of Interest
Unspecified

Abstract

Patients with autoimmune diseases often use immunosuppressive medication. The effect of these treatments on the development and maintenance of adequate immunity after a COVID-19 infection and on the upcoming vaccines against Covid-19 is unknown. Research and expected outcomes First, COVID-19-specific immunity is investigated in patients and healthy people after a COVID-19 infection. In the second phase, the response to a COVID-19 vaccination between infected patients and healthy people is compared. In addition, this response is compared with patients and healthy people without a previous COVID-19 infection. With these results, the hope is to determine the effect of different types of immunosuppressive medication on immunity against COVID-19, so that advice can be given on the optimal vaccination strategy for the many patients with immunosuppression. This study is a collaboration between several university centers, Sanquin Blood Supply and the RIVM (Target to B consortium, T2B).

7 Publications linked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

Evolution of SARS-CoV-2 antibody repertoire after successive mRNA vaccinations under immunosuppressive treatment.

Authors
Keijser JBD, Stalman EW, Wieske L, Steenhuis M, van Dam KPJ, Kummer LYL, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Blanco LF, Verstegen NJM, Keijzer S, van Mierlo G, Cristianawati O, Boogaard AJ, van der Straten K, van Rijswijk J, van Gils MJ, Ten Brinke A, van Ham SM, Kuijpers TW, Eftimov F, Rispens T, T2B! Immunity against SARS-CoV-2 study group.
Publish Year
2025
Journal
EBioMedicine
DOI
10.1016/j.ebiom.2025.105620

View at Europe PMC

Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy.

Authors
van Buchem-Post NF, Ouwerkerk W, Stalman EW, van Dam KPJ, Wieske L, Bekkenk MW, Wolkerstorfer A, Spuls P, Musters AH, Bosma AL, Hijnen DJ, Eftimov F, Luiten RM, T2B! immunity against SARS‐CoV‐2 study group, van Kempen ZLE, Stalman EW, Steenhuis M, Kummer LYL, van Dam KPJ, Ten Brinke A, van Ham SM, Kuijpers T, Rispens T, Eftimov F, Wieske L, Killestein J, Kooi AJV, Raaphorst J, Zwinderman AHK, Löwenberg M, Volkers AG, D'Haens GRAM, Takkenberg RB, Tas SW, Hilhorst ML, Vegting Y, Bemelman FJ, Verstegen NJM, Fernandez L, Keijzer S, Keijser JBD, Cristianawati O, Voskuyl AE, Broens B, Sanchez AP, Nejentsev S, Mirfazeli ES, Wolbink GJ, Boekel L, Rutgers BA, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart R, Teng Y, Busch MH, Brusse E, van Doorn PA, Baars M, Schreurs C, van der Pol WL, Goedee HS, van Els CACM, de Wit J.
Publish Year
2025
Journal
The Journal of dermatology
DOI
10.1111/1346-8138.17664

View at Europe PMC

Patient-reported daily functioning after SARS-CoV-2 vaccinations in autoimmune neuromuscular diseases.

Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.

Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.

Authors
van Dam KPJ, Wieske L, Stalman EW, Kummer LYL, Roosen J, van Kempen ZLE, Killestein J, Volkers AG, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Sanchez AP, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Keijser JBD, Cristianawati O, Rispens T, Brinke AT, Verstegen NJM, Marieke van Ham S, Tas SW, Kuijpers TW, Eftimov F, T2B! Immunity against SARS-CoV-2 study group.
Publish Year
2023
Journal
Journal of autoimmunity
DOI
10.1016/j.jaut.2022.102984

View at Europe PMC

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.

Authors
Palomares Cabeza V, Kummer LYL, Wieske L, Hagen RR, Duurland M, Konijn VAL, van Dam KPJ, Stalman EW, van de Sandt CE, Boekel L, Verstegen NJM, Steenhuis M, Rispens T, Tas SW, Wolbink G, Killestein J, Kuijpers TW, van Ham SM, Eftimov F, Brinke AT, van Kempen ZLE, Target-to-B! (T2B!) SARS-CoV-2 study group.
Publish Year
2022
Journal
Neurology(R) neuroimmunology & neuroinflammation
DOI
10.1212/nxi.0000000000001178

View at Europe PMC

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.

Authors
Boekel L, Stalman EW, Wieske L, Hooijberg F, van Dam KPJ, Besten YR, Kummer LYL, Steenhuis M, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Parra Sanchez A, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, van der Pol WL, Goedee HS, Vogelzang EH, Leeuw M, Atiqi S, van Vollenhoven R, Gerritsen M, van der Horst-Bruinsma IE, Lems WF, Nurmohamed MT, Boers M, Keijzer S, Keijser J, van de Sandt C, Boogaard A, Cristianawati O, Ten Brinke A, Verstegen NJM, Zwinderman KAH, van Ham SM, Rispens T, Kuijpers TW, Wolbink G, Eftimov F, T2B! immunity against SARS-CoV-2 study group.
Publish Year
2022
Journal
The Lancet. Rheumatology
DOI
10.1016/s2665-9913(22)00102-3

View at Europe PMC